SmartTarget Improves Prostate Cancer Detection During Biopsies, Study Says

SmartTarget Improves Prostate Cancer Detection During Biopsies, Study Says
SmartTarget, an image fusion software that combines magnetic resonance imaging (MRI) and ultrasounds, should be used along with a visual review of MRI scans to conduct biopsies in patients with suspected prostate cancer, a study shows. The study, "The SmartTarget Biopsy Trial: A Prospective, Within-person Randomised, Blinded Trial Comparing the Accuracy of Visual-registration and Magnetic Resonance Imaging/Ultrasound Image-fusion Targeted Biopsies for Prostate Cancer Risk Stratification," was published in European Urology. Prostate cancer diagnosis depends on accurate identification of the tumor during an invasive biopsy. Until recently, doctors performed a biopsy using an ultrasound, without knowing the location of the tumor. But the reliability of the approach was low and many tumors were not detected. In recent years, the addition of MRI imaging — which indicates the most likely location of the tumor before performing the biopsy — has shown good results, increasing the percentage of identified tumors and making the procedure less invasive. "Prostate cancer detection has been improving at a very fast rate in recent years, and this technology pushes the science forward even further, enabling clinicians to pick up prostate cancer quickly so that patients can access the right treatment early enough," professor Hashim Ahmed, co-senior author of the study, said in a press release. MRI-guided biopsies require an experienced surgeon who can translate MRI findings into what he is seeing on the ultrasound during a biopsy, a strategy called traditional visual registration. To facilitate the procedure, a team of engineers and medical researchers at University College London developed SmartTarget, software that helps locate tumors by fusing the MRI imaging
Subscribe or to access all post and page content.